Dutch-based medical device company ViCentra, which
commercialises the Kaleido insulin patch pump system, has raised an additional
$13 million as part of its Series D financing, bringing the total round to $98
million. The funding includes new capital from ROM Utrecht Region and a
consortium of Dutch investors, including Venturing Tech, alongside increased
support from existing investor Innovation Industries.
ViCentra develops and manufactures Kaleido, a compact and
discreet alternative to traditional insulin pumps designed to support diabetes
management. Kaleido is positioned as the smallest, lightest, and most precise
insulin patch pump in its class, delivering automated insulin therapy through
integration with Diabeloop’s clinically validated hybrid closed-loop
algorithms, DBLG1 and DBLG2.
Designed to resemble personal technology rather than a
conventional medical device, Kaleido combines functionality with thoughtful
industrial design. It is made from premium materials and features customizable
aluminium shells in ten color options, giving users flexibility in how and where
the pump is worn while supporting everyday therapy management.
The new round follows the $85 million raised in September
2025. Commenting on the investment, CEO Tom Arnold said the past year marked a
period of significant progress for the company, adding that the funding will
support expanded manufacturing and stronger commercial operations and customer
support.
Our goal for 2026 is clear: convert strong demand into
satisfied users through uncompromising quality and performance, and nearly
triple our European user base by the end of 2026.
With this funding, ViCentra plans to scale manufacturing,
strengthen commercial execution in Germany, the Netherlands, and France, and
accelerate preparations for bringing its next-generation Kaleido system to the
U.S. market, positioning the company for continued growth in the insulin
delivery sector.